Iron Overload Clinical Trial
— FeMicrobiomeOfficial title:
Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption
The FeMicrobiome study will evaluate gut microbiome features and their relationships with dietary iron absorption in healthy adults. The investigators hypothesize that (1) the gut microbiota can be shaped by the heme and non-heme Fe content of the diet and that (2) this will influence individual variation in dietary Fe absorption.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | January 14, 2026 |
Est. primary completion date | January 14, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Healthy adults - Age between 18- 40y - Non-smoking - Not currently taking vitamin, mineral, prebiotic, and probiotic supplements. - Females: premenopausal and not pregnant or lactating - No preexisting medical complications (such as eating disorders, hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or taking medications known to influence iron homeostasis) - Body mass index (BMI) between 18 - 27 kg/m2. Exclusion Criteria: - BMI <18 or > 27 kg/m2, - Age <18 y or > 40y, - Not of Northern European or East Asian ancestry - Smoking - Pregnancy, lactating - Have gastrointestinal disorders/malabsorption diseases/hemoglobinopathies/dietary restrictions/steroid use/ medication use of medications known to impact iron status, iron utilization or inflammatory status - Currently take vitamin, mineral, prebiotic, and probiotic supplements. - Recently received antibiotic treatment |
Country | Name | City | State |
---|---|---|---|
United States | Cornell University | Ithaca | New York |
Lead Sponsor | Collaborator |
---|---|
Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The percent of non-heme iron absorption | Percent non-heme iron absorption will be determined by red blood cell iron incorporation of stable 57Fe | 2-week | |
Primary | The concentrations of hemoglobin | The concentrations of hemoglobin (d/dL) | baseline | |
Primary | The concentrations of ferritin | The concentrations of ferritin (ug/L) | baseline | |
Primary | Serum transferrin receptor | Serum transferrin receptor in mg/L | baseline | |
Primary | The hematocrit | Blood hematocrit in % | baseline | |
Primary | Habitual dietary information | Habitual dietary information will be obtained from Diet History Questionnaire III. | baseline | |
Primary | Dietary information on the day prior to iron dosing | Detailed dietary information about all foods and beverages consumed on the day prior to iron dosing will be obtained from the Automated Self-Administered 24-Hour Dietary Assessment Tool. Total iron intake will be presented as a proportion of the daily iron requirement. Total heme and non-heme iron intakes will be quantified. | baseline | |
Primary | Gut microbiome composition | Shotgun metagenomic sequencing will be performed to assess the gut microbiome compositions and gene functional features in a stool sample collected within one day before or after iron dosing. | baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04423237 -
Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT
|
||
Completed |
NCT04614779 -
Long-term Clinical Study of CN128 in Thalassemia Patients
|
Phase 2 | |
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT02833493 -
Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload
|
N/A | |
Completed |
NCT02164253 -
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
|
Phase 2 | |
Completed |
NCT00512226 -
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
|
N/A | |
Completed |
NCT00901199 -
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
|
Phase 2 | |
Recruiting |
NCT00378469 -
Study of the Effects of Muscular Activity on Iron Metabolism
|
N/A | |
Completed |
NCT00117507 -
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
|
Phase 4 | |
Completed |
NCT00138684 -
Cytochrome P450 2E1 and Iron Overload
|
Phase 2 | |
Completed |
NCT03990181 -
Inhibiting Dietary Iron Absorption in Subjects With Hereditary Hemochromatosis by a Natural Polyphenol Supplement
|
N/A | |
Terminated |
NCT02274233 -
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
|
Phase 1 | |
Active, not recruiting |
NCT01443195 -
Iron Metabolism in Small Pre Term Newborns
|
N/A | |
Completed |
NCT01546415 -
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
|
Phase 4 | |
Completed |
NCT01572818 -
Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients
|
N/A | |
Not yet recruiting |
NCT00980421 -
Safety of Various Mode of Delivery of Iron Supplement on Iron Toxicity Markers in Preschool Children
|
Phase 3 | |
Completed |
NCT01047098 -
Effects of Taking Prenatal Vitamin-mineral Supplements During Lactation on Iron Status and Markers of Oxidation
|
N/A | |
Recruiting |
NCT05294471 -
Fully Automated High-Throughput Quantitative MRI of the Liver
|
||
Completed |
NCT03591575 -
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
|
Phase 4 | |
Active, not recruiting |
NCT00907283 -
Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
|
Phase 2 |